Inventage Lab will be attending the World Congress for Hair Research (WCHR) 2026, taking place May 28–31, 2026 at COEX, Seoul, South Korea.
WCHR is the world's foremost academic conference in hair and scalp research, bringing together clinicians, researchers, and pharmaceutical and biotech professionals to share the latest scientific findings and innovations in therapeutic technology.
Inventage Lab is a publicly listed, clinical-stage biotech headquartered in South Korea, developing proprietary microfluidic-based drug delivery platforms. Our portfolio includes DrugFluidic®, a platform for long-acting injectable (LAI) formulations of small molecules and peptides; BioFluidic™, designed to optimize subcutaneous delivery of antibodies and protein therapeutics; and GeneFluidic®, an LNP-based delivery platform for nucleic acid therapeutics. Notably, IVL3001, our lead hair loss pipeline developed on the DrugFluidic® platform, is a once-monthly long-acting injectable formulation of Finasteride currently under clinical development, designed to dramatically improve patient compliance over conventional daily oral tablets.
At WCHR 2026, Inventage Lab will be available for meetings to explore co-development, licensing, and partnership opportunities centered on IVL3001 and our broader hair loss pipeline with global researchers and industry partners.
